Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that in patients with alopecia areata and atopic dermatitis, 61.5% showed improvement with dupilumab treatment, but 38.5% experienced worsened or new-onset alopecia areata, with higher baseline IgE levels linked to better responses.

In this study, researchers found that cytokine dysregulation linked to genetic background is present in both patients and healthy but genetically related individuals in two autoimmune skin diseases, Pemphigus vulgaris and Alopecia areata, suggesting that protective immune mechanisms may prevent disease manifestation in predisposed individuals.

This study found that FZD2 is crucial for hair follicle formation and postnatal growth in mice and has a novel role in regulating early epidermal development, including stratification and cornification.

Hidradenitis Suppurativa is a chronic skin condition best treated early with surgery for better outcomes and less recurrence.

This report describes two cases where topical squaric acid dibutylester application in alopecia totalis patients led to severe pustular lesions, necessitating systemic prednisolone treatment.

This letter discusses a case of Hepatitis C-related vitiligo in a patient with Ivemark syndrome and presents no new clinical results.

Alopecia totalis/universalis involves more intense immune activity and inflammation than patchy alopecia areata.

This review highlights that alopecia areata is characterized by three immune endotypes, and while JAK inhibitors offer temporary control, upcoming multi-omics diagnostics and immune reprogramming strategies may achieve longer-lasting remission, according to this analysis.

This review examines the interconnected processes of atopic dermatitis and alopecia areata, highlighting shared immune imbalances, genetic factors, and microbiome influences, while analyzing current and emerging treatments and identifying gaps in understanding these overlapping conditions.

In this scoping review and meta-analysis, researchers found that patients with alopecia areata show a complex serum chemokine profile, predominantly involving Th1- and Th2-associated chemokines, suggesting that broader immunomodulatory strategies might address the diverse immune dysregulation observed in the disease.

Using high-throughput proteomics, this study identified 34 differentially expressed proteins in the lesional skin of adults with scalp psoriasis, suggesting a cytokine storm response linked to bacterial antigens.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

This review discusses the relationship between allergies and alopecia areata, highlighting potential roles for anti-allergy and desensitization therapies, but reports no new clinical results.

This study found that acne lesions and nonlesional skin in mild-to-moderate acne patients showed significant Th17-skewing and increased antimicrobials, suggesting systemic targets like IL-17/IL-23/IL-36 could be therapeutic.

In this study, clinical case reports of three patients with advanced plaque scalp psoriasis treated with combination therapy including betamethasone dipropionate cream showed symptom relief within 2–3 weeks, highlighting the effectiveness of this treatment approach for managing scalp psoriasis.

In this single-cell transcriptomic study, researchers analyzed AA scalp samples and found distinct immune and nonimmune cell activation patterns, with elevated TH1/TH2 and JAK/STAT markers potentially contributing to hair follicle immune privilege disruption and disease severity.

This review highlights advances in understanding alopecia areata as a systemic disease involving genetic, immune, and environmental factors, noting new treatments like Janus kinase inhibitors but acknowledging challenges in long-term safety and accessibility.

This study observed that patients using dupilumab for atopic dermatitis or chronic rhinosinusitis with nasal polyps may experience new-onset or worsening paradoxical alopecia areata, potentially due to unopposed Th1/Th17 immune activity following Th2 pathway blockade.

This case report details the development of a psoriasiform rash and inflammatory alopecia in a 29-year-old man with severe atopic dermatitis following dupilumab treatment. The authors observed hair regrowth and eczema control after discontinuing dupilumab and beginning treatment with abrocitinib.

In this study involving a murine skin infection model, researchers found that the Trichophyton mentagrophytes strain TIMM 2789, specific to rodents, induced typical symptoms of superficial dermatophytosis, while revealing that the fungal gene SUB6 is not essential for virulence.

Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.

This study identified specific genes upregulated in skin γδ T cells involved in alopecia areata, with findings suggesting these cells contribute to disease pathogenesis through inflammatory and Th1 response mechanisms in mouse and possibly human skin.

In this study, researchers demonstrated that CD4 T cells from skin-draining lymph nodes in mice with alopecia areata can transfer the disease to recipient mice, revealing a critical role for CD4 T cells in disease development and suggesting potential therapeutic targets.

Lasheras-Pérez et al. reported that JAK3 and TYK2 proteins are activated in certain forms of primary cicatricial alopecia, suggesting the JAK/TYK/STAT pathway as a potential therapeutic target for these conditions.

This study conducted a scoping review and meta-analysis revealing a complex chemokine profile in alopecia areata patients, with elevated Th1, Th2, and other immune pathway chemokines, suggesting broader immunomodulatory strategies may help address the disease's multifaceted immune dysregulation.

In this scoping review and meta-analysis, researchers found that patients with alopecia areata exhibit complex chemokine profiles, with elevated levels of Th1, Th2, and other immune pathway-associated chemokines, suggesting the potential for broad immunomodulatory strategies to address the disease's immune dysregulation.

In this case report, researchers documented a 71-year-old woman with both alopecia areata and bullous pemphigoid who showed significant improvement using dupilumab after other treatments failed, highlighting its potential for autoimmune diseases with overlapping inflammatory mechanisms.

This study conducted a meta-analysis of gene expression data from alopecia areata patients, identifying 5109 differentially expressed genes and highlighting enriched pathways like JAK-STAT signaling, providing insights into the disease's pathogenesis and potential treatment targets.

This case report details a 47-year-old female with atopic dermatitis who developed alopecia areata after six months on dupilumab therapy; treatment discontinuation and other interventions led to complete hair regrowth, suggesting dupilumab may trigger alopecia areata in patients with atopic or autoimmune predispositions.

This review discusses immunological abnormalities in PCOS, focusing on inflammation and autoantibody production, and reports no new results; it suggests exploring new therapeutic drug targets.